Raman Sehgal’s career accomplishments include international best-selling author (The Floundering Founder), co-founder of life sciences recruitment firm Lead Candidate, and founder & host of the Molecule to Market podcast. On the Business of Biotech, Raman brings his unique and multifaceted perspectives on the biopharma outsourcing space, the bear biotech markets, and how both are impacting the work of early- and clinical-stage biopharma leaders. Listen now and subscribe so you never miss an episode.
With many biotherapeutics a strong immunogenic response can limit the effectiveness of the treatment or cause a more serious illness. This remains a challenge for scientists as the underlying mechanisms of unwanted immunogenicity still aren’t completely understood. Detecting and preventing unwanted sources of immunogenicity as early in the discovery process as possible has become a top priority for research organizations since biotherapeutic development becomes increasingly costly as it moves downstream.
A leading biotech company working in the targeted protein degradation space was looking for fast delivery of the compounds, open, transparent, and on-time communication, and flexibility and ability to scale.